There is a new article from
https://investingnews.com/daily/australia-investing/cbd-stocks-on-the-asx/

A Guide to Investing in CBD Stocks on the ASX

Another big player in the CBD space in Australia is Botanix Pharmaceuticals (ASX:BDA), a clinical stage CBD exploration company with a market cap of AU$98.1 million.

Botanix is another of the biotech stocks with ties to the cannabis sector as it seeks to find treatments for skin diseases including acne, psoriasis, dermatitis and rosacea with its transdermal delivery system using CBD. The company is in the process of preparing the first human trials of a proprietary drug system that delivers synthetic CBD-based medicines to the skin.

Botanix recently teamed up with pharmaceutical-grade CBD provider Purisys in a supply agreement that covers Botanix’s need for synthetic CBD as it continues its clinical trials for products in its pipeline.

The company’s research efforts were helped by a grant from the federal government’s AusIndustry department in October, which will be used to create new synthetic and patentable versions of the extract and explore its antimicrobial properties.

and it looks like it has also been translated into chinese on another site
https://www.investank.com/news/detail/446847?from_channel_id=50